Skip to main content

Company

Telix Pharmaceuticals Ltd

ASX:TLX

Telix Pharmaceuticals Ltd (ASX:TLX) is listed on the Australian Securities Exchange.

12 stories

Inside Biotech: Telix rally meets reality check as $600m raise tempers Regeneron-driven surge

By Proactive 15/04

The Morning Catch-Up: ASX set to fall as Middle East escalation lifts oil and rattles markets

By Proactive 13/04

Financial Services

Housing shortages, market fear and what comes next for Australian investors

By Proactive 20/03

Inside Biotech: Telix expands AI-driven imaging push with research partnership

By Proactive 05/03

Telix jumps 6% as FY25 revenue surges 56% and FY26 outlook points to further growth

By Proactive 20/02

Inside Biotech: Telix delivers on growth, but confidence remains fragile

By Proactive 21/01

Telix NDA for Illuccix accepted in China

By Proactive 20/01

Illuccix China Phase 3 study supports Telix Pharmaceuticals' regulatory pathway

By Proactive 22/12/2025

Inside Biotech: Telix, regulatory resets and the weight of unresolved risk

By Proactive 17/12/2025

Telix Pharmaceiuticals sees sell-off on back of class actions

By Proactive 14/11/2025

Pharma & Biotech

Telix shares surge after FDA agrees to resubmission pathway for Pixclara

By Proactive 09/09/2025

Telix Pharmaceuticals shares jump after signing partnership deal for Greater China market

The Melbourne-headquartered biopharmaceutical company is focused on developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer.

By Proactive 03/11/2020